Organization
Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China
9 abstracts
Abstract
The safety of atezolizumab plus bevacizumab (atezo/bev) treatment in Chinese patients (pts) with hepatocellular carcinoma (HCC) with active hepatitis B virus (HBV) infection: Results from the TALENTop study.Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Department of Hepatobiliary Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou, China, Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China,
Abstract
A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage.Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Qilu Hospital of Shandong University,
Abstract
Development and validation of a non-invasive cfDNA targeted sequencing assay for early-stage hepatocellular carcinoma detection using cfDNA methylation and fragmentomics.Org: Singlera Genomics Ltd., Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch),
Abstract
Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Cornell University, National University Hospital, Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University,
Abstract
A combinatorial model of plasma proteins and LDCT imaging and the diagnosis of pulmonary nodules.Org: Experimental Animal Center, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, West China Hospital, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Updated.Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Ultra-sensitive baseline-informed MRD assay to predict prognosis outcomes in patients with resectable hepatocellular carcinoma.Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Huidu Shanghai Medical Sciences, Ltd.,
Abstract
The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.Org: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University,
Abstract
Technical performance of cancer detection and TOO identification of PanSeer7, a targeted bisulfite sequencing assay for non-invasive multi-cancer detection.Org: Singlera Genomics Ltd., Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch),